<DOC>
	<DOCNO>NCT00113334</DOCNO>
	<brief_summary>The goal clinical research study see individual advance head neck cancer respond treatment new drug thrombospondin ( ABT-510 ) learn effective destroying cancer cell . The safety ABT-510 effect ABT-510 cell body also study .</brief_summary>
	<brief_title>Study ABT-510 ( Thrombospondin Analogue ) Patients With Advanced Head Neck Cancer</brief_title>
	<detailed_description>This phase Ib/II , single-center , open-label study design assess safety , tolerability , pharmacokinetics , biologic efficacy ABT-510 ( thrombospondin ) . Participants patient incurable head neck cancer . Patients begin fix dose level thrombospondin subcutaneously twice daily . Cycles treatment 28 day ( 4 week ) . Patients treat thrombospondin progression tumor toxicity .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Patient histologically proven squamous cell carcinoma head neck amenable curative therapy , include radiation surgery ( include surgery follow induction chemotherapy chemoradiation ) . Patient 's tumor biopsy accessible . Patient Karnofsky performance status &gt; /= 70 . Patient adequate bone marrow function : White blood count ( WBC ) &gt; /= 3,000 cells/mm3 , absolute neutrophil count ( ANC ) &gt; /= 1,500 cells/mm3 , platelet count &gt; /= 100,000 cells/mm3 , Hgb &gt; /= 9.0 g/dL . Patient adequate liver function : total bilirubin level &lt; /= 2.0 mg/dL , albumin &gt; /= 2.5 g/dL . Transaminases ( SGOT and/or SGPT ) may 2.5 * upper limit normal ( ULN ) alkaline phosphatase &lt; /= ULN , alkaline phosphatase may 4 x ULN transaminases &lt; /= ULN . However , patient transaminase elevation &gt; 1.5 * ULN alkaline phosphatase &gt; 2.5 * ULN eligible study . Patient serum creatinine &lt; 2 mg/dl Patient sign write informed consent . Patient may receive number prior chemotherapeutic regimen recurrent metastatic disease . The subject must pregnant breastfeeding . All subject ( male female ) practice contraception ( e.g. , barrier , hormonal , intrauterine device [ IUD ] ) abstain sexual intercourse study two month follow completion therapy . The subject able selfadminister caregiver reliably administer subcutaneous ( SC ) injection . Patient &gt; /= 18 year age . No biopsy accessible tissue . Patient receive prior radiation therapy biopsy site within past 3 month . ( Patient may receive palliative radiation within past 2 week , biopsy site . ) Patient exhibits confusion , disorientation , history major psychiatric illness may impair patient 's understanding informed consent . Patient require total parenteral nutrition lipid . Patient history uncontrolled heart disease include congestive heart failure , angina rest , myocardial infarct last 6 month , uncontrolled hypertension systolic blood pressure ( BP ) &gt; 160 diastolic BP &gt; 90 , systolic blood pressure ( BP ) &lt; 90 symptomatic hypotension , symptomatic potentially lifethreatening tachycardia , bradycardia arrhythmia . Pregnant woman woman currently breastfeed may participate study . All woman childbearing potential must negative pregnancy test within 24 hour prior enrol study . Serious infection intercurrent illness require immediate therapy . The subject history currently exhibit clinically significant cancer relate event bleed ( e.g. , hemoptysis ) . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant event bleed . If subject receive therapeutic anticoagulation therapy , low dose anticoagulation catheter prophylaxis permit ; PT/PTT must within normal limit . The patient history currently exhibit central nervous system ( CNS ) metastasis . Brain magnetic resonance imaging ( MRI ) within 28 day enrollment require confirm absence CNS metastasis . Patient receive chemotherapy biologic therapy within 3 week registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Thrombospondin Analogue</keyword>
	<keyword>ABT-510</keyword>
	<keyword>Antiangiogenic agent</keyword>
	<keyword>Lung</keyword>
	<keyword>Skin</keyword>
	<keyword>Thyroid</keyword>
</DOC>